Vericel Corporation (VCEL) shares plummeted 5.03% in Monday's trading session amid a price target cut by Truist Securities. The investment bank lowered its price target on the biopharmaceutical company's stock to $61 per share from the previous $67 target.
The downward revision in Vericel's price target by Truist Securities analysts appears to have weighed on investor sentiment, contributing to the sharp decline in the stock's price during Monday's intraday trading.